Fierce Pharma

APRIL 7, 2023

Idorsia petitions DEA to de-schedule its insomnia drug—plus Merck and Eisai rivals kdunleavy Fri, 04/07/2023 - 07:52

130

130

Pharmaceutical Technology

MAY 16, 2024

DN-1508052 is under clinical development by Shanghai De Novo Pharmatech and currently in Phase I for Hepatocellular Carcinoma. According to…

40

40

PharmExec

DECEMBER 28, 2023

As companies continued to expand their DE&I efforts, Pharm Exec was there to cover it in 2023.

52

52

Rep-Lite

OCTOBER 13, 2023

However, with the right strategies and partnerships, you can de-risk the team-building process. Thorough Screening and Evaluation: To de-risk the hiring process, it’s crucial to thoroughly screen and evaluate candidates. De-risking the process of building a team is essential for long-term success.

Recruitment 52

Recruitment Specialization Networking Medical 52

Fierce Pharma

AUGUST 17, 2023

On a long road full of potholes, Ipsen has reached its destination—gaining FDA approval for Sohonos to treat an ultra-rare bone disease.

FDA 246

FDA 246

Pharmaceutical Commerce

DECEMBER 13, 2023

The conference hosts a diversity, equity, and inclusion (DE&I) Summit featuring personal insights and experiences.

52

52

PharmaVoice

APRIL 23, 2024

Mark Wildgust, vice president of global medical affairs for J&J's oncology division, shares strategies for making clinical trials gender- and trans-inclusive.

Medical 81

Medical 81

pharmaphorum

APRIL 10, 2024

e-therapeutics is the latest UK biotech to say it plans to delist from the AIM, citing a lack of interest from institutional investors.

92

92

Rep-Lite

AUGUST 5, 2020

In this episode of Med Tech Gurus, Mr. Rick Barnett CEO and Founder of Rep-Lite discuss how his company can de-risk the hiring process. Rick explains how his company Rep-Lite will find the right person for the position, hire them then contract this individual out to your company.

Sales 52

Sales 52

pharmaphorum

OCTOBER 26, 2022

The post Normunity de-stealths, launches Series A immune normalisers appeared first on. Based out of Queen Mary University of London and the Barts Cancer Institute – one of the top cancer research centres in the UK – VacV BioTx has a $3 million investment from Proxima Ventures.

Medicine 52

Medicine Leads Medical Patients 52

Fierce Pharma

AUGUST 8, 2023

Big changes are brewing at Emergent BioSolutions, as the beleaguered contract manufacturer puts its CDMO business on the back burner in a bid to shore up its core medical countermeasures and Narcan | Emergent is de-emphasizing its focus on its CDMO services business.

Manufacturing 222

Manufacturing Medical 222

European Pharmaceutical Review

MARCH 5, 2024

BeiGene has appointed Pilar de la Rocha as its new Head of Europe, Global Clinical Operations. Pilar de la Rocha brings more than two decades of experience in oncology clinical development to the role, according to Beigene. The company highlighted that 35 percent of patients enrolled in its clinical trials are based in Europe.

Medicine 91

Medicine Leads Medical Manufacturing 91

PharmaVoice

SEPTEMBER 18, 2023

The visual inspection of injectable drug product has been a regulatory requirement since 1936, however, successful implementation of the standard has been challenging for many organizations.

52

52

PharmaVoice

NOVEMBER 4, 2022

How companies can work to include people with disabilities into broader equity aims.

98

98

PharmaVoice

NOVEMBER 11, 2022

Recorded just weeks before his passing, our sit-down interview with the legendary medical sciences entrepreneur showcased his passion for pushing the industry toward its next frontier.

Medical science 119

Medical science Medical 119

PharmaTimes

APRIL 26, 2023

Vital link-up aims to expand ColoAlert detection tests in Europe and increase early cancer diagnosis

78

78

Pharmaceutical Commerce

APRIL 18, 2024

Panel discussion addresses how DE&I can successfully tackle systemic biases and more.

105

105

pharmaphorum

MAY 13, 2024

The latest tranche of investment – at Vitry-sur-Seine in Val de Marne, Le Trait in Seine-Maritime, and Lyon Gerland in the Rhône region – is part of a drive to reduce the reliance of France and the wider EU on manufacturing capacity in other parts of the world and boost supply chain security and resiliency. billion programme in the country.

Manufacturing 85

Manufacturing 85

PharmaTech

APRIL 30, 2024

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

69

69

MedCity News

OCTOBER 4, 2022

Alban de La Sablière, global head of partnering at Sanofi for the past six years, has joined artificial intelligence biotech Owkin as its first chief business officer. In addition to finding more business partnerships, de La Sablière will also oversee expansion of Owkin’s internal drug and diagnostics pipeline.

Pharma 94

Pharma Biopharma 94

PharmaVoice

APRIL 19, 2023

A chemical engineer by training, Brii’s chief technology officer is applying her experience to solve research problems from the clinic to commercial development.

Engineering 52

Engineering Training 52

MedCity News

OCTOBER 16, 2023

Some of the measures Mayo is taking include running analyses on how well algorithms perform across various subgroups and training models only on internal de-identified data. At HLTH, Mayo Clinic Platform President John Halamka gave a window into how his health system is mitigating generative AI risks.

Training 127

Training Healthcare Healthcare 127

PharmExec

MAY 14, 2024

Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive (..)

Marketing 52

Marketing Healthcare Healthcare Pharmaceutical 52

Pharmaceutical Commerce

OCTOBER 30, 2023

Effort displays the diverse perspectives, skills, and people involved with the healthcare supply chain, as industry aims to continue to push DE&I forward.

Healthcare 105

Healthcare Healthcare 105

pharmaphorum

JANUARY 29, 2024

The complaint has been brought against Gotham City and co-founders Daniel Yu and Cyrus de Weck, along with other defendants, and accuses them of being “predatory short sellers…who illicitly profit from their rigged short-and-distort schemes.”

105

105

Pharma Leaders

APRIL 20, 2023

The FDA has updated emergency use authorizations for the Pfizer-BioNTech and Moderna COVID-19 bivalent mRNA vaccines to allow individuals 65 years and older to receive a second booster dose at least four months after the first bivalent dose. The FDA also authorized use of the current bivalent vaccines for everyone six months of age and older.

FDA 52

FDA 52

MedCity News

JANUARY 8, 2024

In a report, the investment bank said big pharmas are looking for deals involving de-risked assets. Johnson & Johnson’s acquisition of antibody drug conjugate developer Ambrx Biopharma comes as Novartis and Merck also unveiled M&A deals on the first day of the J.P. Morgan Healthcare conference.

Biopharma 90

Biopharma Pharma Healthcare Healthcare 90

MedCity News

OCTOBER 29, 2023

A drug development approach that makes use of hybrid AI can de-risk drug development while simultaneously removing other barriers to success. In other words, it has the power to significantly reduce the drug development timeline, and ultimately, save more lives.

Biopharma 97

Biopharma 97

MedCity News

JANUARY 9, 2024

She applauded the rule for preserving TEFCA as a voluntary framework and for establishing FHIR-based interoperability as the industry’s de facto standard.

Healthcare 97

Healthcare Healthcare Patients 97

PharmExec

APRIL 25, 2024

In this Pharmaceutical Executive video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but address their specific healthcare needs

Patients 52

Patients Healthcare Healthcare Marketing 52

PharmaTech

AUGUST 8, 2023

Catalent's Martin De Brauwere and Maria Lopez react to cell therapy innovations and highlight strategies to optimize the drug development and manufacturing process with assistance from a CDMO.

Manufacturing 98

Manufacturing 98

Pharmaceutical Commerce

OCTOBER 24, 2023

Paris location helps increase 3PL’s air freight capabilities.

52

52

PharmExec

JULY 10, 2023

In today's changing workplace environment—one forever altered by the pandemic and the new approaches it spawned—employees at all levels play a vital role in developing and advancing inclusive behaviors across an organization and beyond.

Pharma 52

Pharma 52

PharmaTech

OCTOBER 16, 2023

Enrico Barichello, Stevanato Group, discusses the risks associated with the interaction between primary packaging and complex novel therapeutics and describes how to prevent or manage concerns utilizing newer, pre-sterilized syringe systems that have more unique characteristics.

Management 52

Management 52

European Pharmaceutical Review

MAY 14, 2024

The sites are in Vitry-sur-Seine (Val de Marne), Le Trait (Seine-Maritime) and Lyon Gerland (Rhône). An investment of €250 million will used to build Europe’s largest flu vaccine production unit in Val de Reuil. The facility will be low-carbon. Sanofi shared that it plans to launch in 2025.

Medicine 64

Medicine Manufacturing Pharmaceutical 64

MedCity News

JANUARY 26, 2023

commercial rollout of the company’s implantable device, which received FDA de novo clearance in 2020. Miach Orthopaedics — a medical device company focused on restoring torn ACLs instead of reconstructing them — recently received $40 million in funding. The capital will be used to expand the U.S.

Medical 107

Medical FDA 107

MedCity News

FEBRUARY 7, 2023

Francesca de Quesada Covey, chief investment officer at investment firm TheVentureCity, believes the women’s health sector will come into its own in the next few years. She said startups focused on improving care delivery will probably have the easiest time raising funds of all the companies in the femtech space.

108

108